GlassScriptPhysician profile
Yunying Chen
NPI 1558944520
$80,164.58
in general payments reported to CMS, 2019-2025
25 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $46.33 · 2023: $17K · 2024: $30K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $19K · Consulting Fee: $11K · Honoraria: $6,912 · Food and Beverage: $4,831 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,330 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,709.52 |
| Travel and Lodging | $18,778.99 |
| Consulting Fee | $10,738.50 |
| Honoraria | $6,912.00 |
| Food and Beverage | $4,830.91 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,330.00 |
| Education | $142.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52,962.96 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $18,539.23 | 2021-2025 | Rezlidhia, Tavalisse, Rezlidhia |
| Biolinerx USA, INC. | $2,703.69 | 2024 | Aphexda |
| Autolus INC | $2,158.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,366.91 | 2024 | Reblozyl |
| Janssen Biotech, INC. | $669.09 | 2023-2025 | Darzalex, Carvykti, Talvey |
| Incyte Corporation | $394.48 | 2021-2025 | Niktimvo |
| Lilly USA, LLC | $213.58 | 2021 | |
| Abbvie INC. | $173.56 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $146.38 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $124.36 | 2021 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Talvey |
| Daiichi Sankyo INC. | $110.67 | 2025 | Vanflyta |
| Astrazeneca Pharmaceuticals LP | $99.30 | 2025 | Calquence, Enhertu |
| Celgene Corporation | $88.44 | 2023-2024 | Reblozyl |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.91 | 2022-2024 | |
| Seagen INC. | $37.53 | 2023 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $34.97 | 2025 | Hyqvia |
| Secura Bio, INC. | $29.81 | 2025 | Copiktra |
| Glaxosmithkline, LLC. | $29.22 | 2025 | Blenrep |
| Geron Corporation | $27.09 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $25.54 | 2025 | Brukinsa |
| Legend Biotech USA INC. | $24.32 | 2025 | Carvykti |
| Amgen INC. | $20.63 | 2021 | |
| Sobi, INC | $19.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yunying Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.